Andrew Berchuck

94.1k total citations · 5 hit papers
358 papers, 19.9k citations indexed

About

Andrew Berchuck is a scholar working on Reproductive Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Andrew Berchuck has authored 358 papers receiving a total of 19.9k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Reproductive Medicine, 108 papers in Molecular Biology and 98 papers in Oncology. Recurrent topics in Andrew Berchuck's work include Ovarian cancer diagnosis and treatment (166 papers), Endometrial and Cervical Cancer Treatments (79 papers) and BRCA gene mutations in cancer (39 papers). Andrew Berchuck is often cited by papers focused on Ovarian cancer diagnosis and treatment (166 papers), Endometrial and Cervical Cancer Treatments (79 papers) and BRCA gene mutations in cancer (39 papers). Andrew Berchuck collaborates with scholars based in United States, United Kingdom and Australia. Andrew Berchuck's co-authors include Robert C. Bast, Daniel L. Clarke‐Pearson, Jeffrey R. Marks, John T. Soper, Regina S. Whitaker, Laura J. Havrilesky, Angeles Alvarez Secord, Joellen M. Schildkraut, John I. Risinger and Johnathan M. Lancaster and has published in prestigious journals such as Nature, New England Journal of Medicine and Nature Genetics.

In The Last Decade

Andrew Berchuck

349 papers receiving 19.4k citations

Hit Papers

Oncogenic pathway signatures in human cancers as a... 1990 2026 2002 2014 2005 2004 1990 2011 2018 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    2005 1.5k citations Jeffrey T. Chang, Johnathan M. Lancaster et al. profile →
  2. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer
    2004 741 citations Robert C. Bast, Andrew Berchuck et al. profile →
  3. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.
    1990 649 citations Andrew Berchuck, Regina S. Whitaker et al. profile →
  4. Mechanical Stiffness Grades Metastatic Potential in Patient Tumor Cells and in Cancer Cell Lines
    2011 588 citations Andrew Berchuck et al. profile →
  5. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
    2018 345 citations Lauren C. Peres, Andrew Berchuck et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Berchuck United States 73 8.1k 6.9k 5.8k 4.0k 3.8k 358 19.9k
Karen H. Lu United States 72 7.4k 0.9× 8.3k 1.2× 6.8k 1.2× 5.3k 1.3× 4.8k 1.2× 427 21.6k
Beth Y. Karlan United States 69 8.0k 1.0× 6.6k 1.0× 6.4k 1.1× 2.0k 0.5× 3.9k 1.0× 336 18.9k
Robert L. Coleman United States 72 7.7k 0.9× 9.5k 1.4× 7.7k 1.3× 5.7k 1.4× 3.5k 0.9× 690 23.3k
Amit M. Oza Canada 72 7.4k 0.9× 7.0k 1.0× 10.8k 1.9× 2.3k 0.6× 3.5k 0.9× 599 21.7k
Douglas A. Levine United States 70 9.3k 1.1× 7.3k 1.1× 6.7k 1.2× 4.5k 1.1× 6.3k 1.6× 256 22.4k
Jonathan A. Ledermann United Kingdom 60 4.9k 0.6× 8.0k 1.2× 9.2k 1.6× 2.7k 0.7× 2.2k 0.6× 295 17.4k
Ursula A. Matulonis United States 77 7.9k 1.0× 8.2k 1.2× 13.4k 2.3× 2.0k 0.5× 3.1k 0.8× 443 23.1k
Jalid Sehouli Germany 65 5.8k 0.7× 7.8k 1.1× 5.9k 1.0× 3.8k 0.9× 3.2k 0.8× 866 19.2k
Christian Marth Austria 61 5.8k 0.7× 3.1k 0.5× 5.3k 0.9× 2.2k 0.5× 2.8k 0.7× 411 14.0k
Ross S. Berkowitz United States 66 4.6k 0.6× 5.4k 0.8× 2.7k 0.5× 2.9k 0.7× 2.2k 0.6× 445 18.7k

Countries citing papers authored by Andrew Berchuck

Since Specialization
Citations

This map shows the geographic impact of Andrew Berchuck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Berchuck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Berchuck more than expected).

Fields of papers citing papers by Andrew Berchuck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Berchuck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Berchuck. The network helps show where Andrew Berchuck may publish in the future.

Co-authorship network of co-authors of Andrew Berchuck

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Berchuck. A scholar is included among the top collaborators of Andrew Berchuck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Berchuck. Andrew Berchuck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Whitaker, Regina S., Shonagh Russell, Justin Pollara, et al.. (2024). Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer. Neoplasia. 57. 101056–101056. 5 indexed citations
2.
Davidson, Natalie R., Mollie E. Barnard, Amy Campbell, et al.. (2024). Molecular Subtypes of High-Grade Serous Ovarian Cancer across Racial Groups and Gene Expression Platforms. Cancer Epidemiology Biomarkers & Prevention. 33(8). 1114–1125. 4 indexed citations
3.
Huang, Zhiqing, et al.. (2023). Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness. Scientific Reports. 13(1). 10 indexed citations
4.
Huang, Zhiqing, Eiji Kondoh, Tsukasa Baba, et al.. (2020). Targeting Dormant Ovarian Cancer Cells In Vitro and in an In Vivo Mouse Model of Platinum Resistance. Molecular Cancer Therapeutics. 20(1). 85–95. 5 indexed citations
5.
Bachelder, Robin E., Margaret Kennedy, Po‐Han Chen, et al.. (2015). Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78. Molecular Cancer Therapeutics. 14(3). 747–756. 34 indexed citations
6.
Pearce, Celeste Leigh, Daniel O. Stram, Roberta B. Ness, et al.. (2015). Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers & Prevention. 24(4). 671–676. 71 indexed citations
7.
Secord, Angeles Alvarez, Deanna Teoh, William T. Barry, et al.. (2012). A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer. Clinical Cancer Research. 18(19). 5489–5498. 50 indexed citations
8.
Stevens, Kristen N., Linda E. Kelemen, Xianshu Wang, et al.. (2012). Common Variation in Nemo-Like Kinase Is Associated with Risk of Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 21(3). 523–528. 8 indexed citations
9.
Barnett, Jason C., Laura J. Havrilesky, Nicole D. Fleming, et al.. (2011). Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer. American Journal of Obstetrics and Gynecology. 205(2). 143.e1–143.e6. 22 indexed citations
10.
Barnes, H. John, Kenneth E. Anderson, James N. Petitte, et al.. (2011). Reduction of Ovarian and Oviductal Cancers in Calorie-Restricted Laying Chickens. Cancer Prevention Research. 4(4). 562–567. 18 indexed citations
11.
Matsumura, Noriomi, Zhiqing Huang, Tsukasa Baba, et al.. (2009). Yin Yang 1 Modulates Taxane Response in Epithelial Ovarian Cancer. Molecular Cancer Research. 7(2). 210–220. 48 indexed citations
12.
Berchuck, Andrew, Edwin S. Iversen, Jingqin Luo, et al.. (2009). Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome. Clinical Cancer Research. 15(7). 2448–2455. 60 indexed citations
13.
Coukos, George, Andrew Berchuck, & Robert F. Ozols. (2008). Ovarian cancer : state of the art and future directions in translational research. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 3 indexed citations
14.
Risinger, John I., Gadisetti V.R. Chandramouli, G. Larry Maxwell, et al.. (2007). Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression. Clinical Cancer Research. 13(6). 1713–1719. 59 indexed citations
15.
Jewell, Elizabeth L., Angeles Alvarez Secord, Timothy W. Brotherton, & Andrew Berchuck. (2006). Use of trastuzumab in the treatment of metastatic endometrial cancer. International Journal of Gynecological Cancer. 16(3). 1370–1373. 46 indexed citations
16.
Bidus, Michael A., John I. Risinger, Gadisetti V.R. Chandramouli, et al.. (2006). Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray. Clinical Cancer Research. 12(1). 83–88. 59 indexed citations
17.
18.
Boente, Matthew, Andrew Berchuck, Regina S. Whitaker, et al.. (1998). Suppression of Diacylglycerol Levels by Antibodies Reactive with the c-erbB-2 (HER-2/neu) Gene Product p185c-erbB-2in Breast and Ovarian Cancer Cell Lines. Gynecologic Oncology. 70(1). 49–55. 4 indexed citations
19.
Berchuck, Andrew & Jeff Boyd. (1995). Molecular basis of endometrial cancer. Cancer. 76(S10). 2034–2040. 85 indexed citations
20.
McKenzie, S J, K DeSombre, Donna Hollis, et al.. (1993). Serum levels of HER-2neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 71(12). 3942–3946. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Beth Y. Karlan Breakdown of academic impact, for papers by Robert L. Coleman Breakdown of academic impact, for papers by Amit M. Oza Breakdown of academic impact, for papers by Douglas A. Levine Breakdown of academic impact, for papers by Jonathan A. Ledermann Breakdown of academic impact, for papers by Ursula A. Matulonis Breakdown of academic impact, for papers by Jalid Sehouli Breakdown of academic impact, for papers by Christian Marth Breakdown of academic impact, for papers by Ross S. Berkowitz
Rankless by CCL
2026